Moderna (NASDAQ:MRNA) Stock Gets Price Target Boost from TD Cowen

Moderna (NASDAQ:MRNA) had its price target hoisted by equities research analysts at TD Cowen from $40.00 to $90.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price target would suggest a potential downside of 63.78% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Wednesday, September 9th. Piper Sandler lifted their target price on Moderna from $77.00 to $167.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. Finally, Berenberg Bank increased their price target on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research report on Friday, September 11th. Seven equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $103.95.

Moderna Stock Up 2.7%

NASDAQ:MRNA traded up $6.43 during trading hours on Wednesday, reaching $248.51. The company’s stock had a trading volume of 4,650,982 shares, compared to its average volume of 12,359,348. The company has a market capitalization of $99.21 billion, a P/E ratio of -31.04 and a beta of 1.09. Moderna has a 12 month low of $22.28 and a 12 month high of $248.95. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock has a 50 day moving average price of $163.63 and a two-hundred day moving average price of $93.77.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.13) earnings per share. Equities analysts predict that Moderna will post -6.11 EPS for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the sale, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock worth $33,875,904. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Moderna

Several hedge funds have recently made changes to their positions in the company. Merck & Co. Inc. acquired a new stake in Moderna during the 2nd quarter worth about $161,642,545. Louisiana State Employees Retirement System acquired a new position in shares of Moderna in the first quarter valued at about $899,000. Bank of New York Mellon Corp acquired a new position in shares of Moderna in the second quarter valued at about $119,168,000. Contravisory Investment Management Inc. increased its holdings in shares of Moderna by 1,387.6% in the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after purchasing an additional 22,590 shares during the period. Finally, TD Waterhouse Canada Inc. raised its stake in shares of Moderna by 2,042.6% in the third quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock worth $13,722,000 after purchasing an additional 69,203 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investors are positioning ahead of a closely watched presentation of Phase 3 data for Moderna’s personalized melanoma vaccine, developed with Merck. Positive results could support the case for a major new oncology franchise and are the primary catalyst behind the recent buying interest. Moderna Jumps 7% While Melanoma Vaccine Data Looms
• Positive Sentiment: Coverage highlights Moderna’s transition from a COVID-19 vaccine company toward a cancer-focused biotechnology business. Advancing oncology programs and the possibility of a future product launch are attracting Wall Street attention and broadening the company’s long-term growth narrative. Forget COVID: Moderna Is Turning Into a Cancer Company
• Positive Sentiment: Oddo BHF raised its Moderna price target to $251 from $170, while other analyst commentary has also supported the shares. Higher targets reinforce the bullish sentiment surrounding the melanoma program. Oddo BHF Adjusts Moderna Price Target
• Positive Sentiment: Moderna’s mRNA flu vaccine is becoming available at select pharmacies in Colorado for adults age 50 and older. The rollout offers a potential additional commercial opportunity beyond COVID-19, though its initial availability appears limited. New mRNA Flu Vaccine Available at Select Pharmacies
• Neutral Sentiment: Moderna is expected to feature prominently at ESMO 2026, keeping attention on its cancer pipeline and upcoming clinical disclosures. Merck/Moderna to Headline ESMO 2026
• Negative Sentiment: Some analysts argue that the stock has moved ahead of the evidence and caution investors against “cancer vaccine hype.” With MRNA trading near its 12-month high and the company still reporting losses, disappointing data could trigger a sharp reversal. Moderna: Sell The Cancer Vaccine Hype
• Negative Sentiment: Chief medical officer Stephen Hoge sold shares under a prearranged trading plan. The transaction is not necessarily a negative signal, but insider selling can add caution while the stock is priced for clinical success. Moderna Executive Sells Shares Under Trading Plan

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.